Literature DB >> 2429440

Geographic classification of dengue-2 virus strains by antigen signature analysis.

T P Monath, J R Wands, L J Hill, N V Brown, R A Marciniak, M A Wong, M K Gentry, D S Burke, J A Grant, D W Trent.   

Abstract

Dengue-2 virus strains from different locations were compared by T1-RNAse-resistant oligonucleotide fingerprinting and antigen signature analysis. The latter technique involved construction of radioimmunoassays using monoclonal antibodies that recognize nine distinct dengue-2 type-specific and flavivirus cross-reactive epitopes over a range of antigen concentrations. A statistical method was used to align unknown dengue antigen concentrations in different strain preparations, allowing comparison of binding profiles. Twenty-six dengue-2 virus strains were separated into five distinct groups (topotypes) on the basis of unique RNA fingerprints. Two of these were represented by New Guinea C, the prototype virus isolated in 1944, and a Philippine strain; others were segregated on the basis of greater than or equal to 80% shared oligonucleotides into similarity groups representing Burma/Thailand (8 strains), Puerto Rico (12 strains), and Jamaica (4 strains). Signature analysis of the prototype and four geographic topotype strains revealed striking antigenic differences. In contrast, a high degree of antigenic similarity was found among strains from the same geographic region. Variation between antigenically distinct strains occurred at both type-specific and group-reactive epitopes, but the widest differences appeared at group-reactive determinants. Signature analysis provides a more rapid and simpler means than RNA fingerprinting of monitoring changes or new introductions of dengue virus populations in a geographic region.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429440     DOI: 10.1016/0042-6822(86)90457-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  NS 1 gene sequences from eight dengue-2 viruses and their evolutionary relationships with other dengue-2 viruses.

Authors:  J Blok; A J Gibbs; S M McWilliam; U T Vitarana
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

2.  Restriction enzyme analysis of American region dengue viruses.

Authors:  V Vorndam; R M Nogueira; D W Trent
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

3.  Epitope mapping of dengue 1 virus E glycoprotein using monoclonal antibodies.

Authors:  E Simantini; K Banerjee
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Isolation and characterization of dengue viruses serotype 1 from an epidemic in northern Queensland, Australia.

Authors:  J Blok; B H Kay; R A Hall; B M Gorman
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

5.  Variation of the nucleotide and encoded amino acid sequences of the envelope gene from eight dengue-2 viruses.

Authors:  J Blok; S Samuel; A J Gibbs; U T Vitarana
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 6.  The dengue viruses.

Authors:  E A Henchal; J R Putnak
Journal:  Clin Microbiol Rev       Date:  1990-10       Impact factor: 26.132

7.  Direct sequencing of genomic cDNA fragments amplified by the polymerase chain reaction for molecular epidemiology of dengue-2 viruses.

Authors:  V Deubel; R M Nogueira; M T Drouet; H Zeller; J M Reynes; D Q Ha
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 8.  Dengue: the risk to developed and developing countries.

Authors:  T P Monath
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

Review 9.  Microevolution and virulence of dengue viruses.

Authors:  Rebeca Rico-Hesse
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

10.  The distribution of synonymous codon choice in the translation initiation region of dengue virus.

Authors:  Jian-hua Zhou; Jie Zhang; Dong-jie Sun; Qi Ma; Hao-tai Chen; Li-na Ma; Yao-zhong Ding; Yong-sheng Liu
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.